Oncology disruption demands strategic transformation

The rapidly accelerating complexity of oncology drug development demands a new way of doing business.

To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.

In this In Vivo article, Parthenon-EY Global Head of Life Sciences Kristin Pothier and Executive Director Troy Norris highlight how players can secure a sustainable position in the future oncology ecosystem.

View the full article here.

Download a PDF of the article here.